WO2004087128A1 - Methyl-β-orcinolcarboxylate from lichen (everniastrum cirrhatum) for use for the treatment of fungal infections and cancer - Google Patents
Methyl-β-orcinolcarboxylate from lichen (everniastrum cirrhatum) for use for the treatment of fungal infections and cancer Download PDFInfo
- Publication number
- WO2004087128A1 WO2004087128A1 PCT/IN2003/000097 IN0300097W WO2004087128A1 WO 2004087128 A1 WO2004087128 A1 WO 2004087128A1 IN 0300097 W IN0300097 W IN 0300097W WO 2004087128 A1 WO2004087128 A1 WO 2004087128A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- methyl
- fungus
- lichen
- cancer
- Prior art date
Links
- UUQHKWMIDYRWHH-UHFFFAOYSA-N Methyl beta-orcinolcarboxylate Chemical compound COC(=O)C1=C(C)C=C(O)C(C)=C1O UUQHKWMIDYRWHH-UHFFFAOYSA-N 0.000 title claims abstract description 77
- 206010017533 Fungal infection Diseases 0.000 title claims abstract description 14
- 208000031888 Mycoses Diseases 0.000 title claims abstract description 14
- 241001230280 Hypotrachyna cirrhata Species 0.000 title claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 title claims description 20
- 201000011510 cancer Diseases 0.000 title claims description 20
- 238000011282 treatment Methods 0.000 title claims description 12
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims abstract description 30
- 150000004291 polyenes Chemical class 0.000 claims abstract description 24
- 229960000988 nystatin Drugs 0.000 claims abstract description 13
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims abstract description 13
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 9
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 8
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960004022 clotrimazole Drugs 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 35
- 229940079593 drug Drugs 0.000 claims description 34
- 241000233866 Fungi Species 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 25
- 241000222122 Candida albicans Species 0.000 claims description 17
- 229940095731 candida albicans Drugs 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 12
- 229940121375 antifungal agent Drugs 0.000 claims description 12
- 230000000843 anti-fungal effect Effects 0.000 claims description 10
- 241000282412 Homo Species 0.000 claims description 7
- 230000001093 anti-cancer Effects 0.000 claims description 7
- 210000001072 colon Anatomy 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 210000004185 liver Anatomy 0.000 claims description 7
- 230000002611 ovarian Effects 0.000 claims description 7
- 239000012871 anti-fungal composition Substances 0.000 claims description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 abstract description 13
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 abstract description 7
- 229960003942 amphotericin b Drugs 0.000 abstract description 7
- 230000001717 pathogenic effect Effects 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 description 24
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 7
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 7
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 7
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 7
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 229930183010 Amphotericin Natural products 0.000 description 6
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 6
- 229940009444 amphotericin Drugs 0.000 description 6
- 230000000975 bioactive effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 229930000044 secondary metabolite Natural products 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000192700 Cyanobacteria Species 0.000 description 4
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 4
- 239000000287 crude extract Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 239000002044 hexane fraction Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 239000002038 ethyl acetate fraction Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 244000291564 Allium cepa Species 0.000 description 2
- 235000005255 Allium cepa Nutrition 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 101150039027 ampH gene Proteins 0.000 description 2
- 230000001032 anti-candidal effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000002459 polyene antibiotic agent Substances 0.000 description 2
- 229930001119 polyketide Natural products 0.000 description 2
- 150000003881 polyketide derivatives Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- -1 some Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940126672 traditional medicines Drugs 0.000 description 2
- WEYVVCKOOFYHRW-UHFFFAOYSA-N usnic acid Chemical compound CC12C(=O)C(C(=O)C)=C(O)C=C1OC1=C2C(O)=C(C)C(O)=C1C(C)=O WEYVVCKOOFYHRW-UHFFFAOYSA-N 0.000 description 2
- WZYZDHVPSZCEEP-SJORKVTESA-N (2r,3s)-4-methylidene-5-oxo-2-tridecyloxolane-3-carboxylic acid Chemical compound CCCCCCCCCCCCC[C@H]1OC(=O)C(=C)[C@@H]1C(O)=O WZYZDHVPSZCEEP-SJORKVTESA-N 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- JHEWMLHQNRHTQX-UHFFFAOYSA-N 3-hydroxy-9-methoxy-6-oxo-7-(1-oxopentyl)-1-pentyl-2-benzo[b][1,4]benzodioxepincarboxylic acid Chemical compound O=C1OC2=CC(O)=C(C(O)=O)C(CCCCC)=C2OC2=CC(OC)=CC(C(=O)CCCC)=C21 JHEWMLHQNRHTQX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000228257 Aspergillus sp. Species 0.000 description 1
- 244000187129 Bacopa monnieria Species 0.000 description 1
- 235000015418 Bacopa monnieria Nutrition 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 241000221635 Cladonia Species 0.000 description 1
- 241001197149 Cladonia verticillaris Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- VEGGRTFDFMUBPD-UHFFFAOYSA-N Fumarprotocetraric acid Natural products O1C2=C(C)C(C(O)=O)=C(O)C(COC(=O)C=CC(O)=O)=C2OC(=O)C2=C1C(C=O)=C(O)C=C2C VEGGRTFDFMUBPD-UHFFFAOYSA-N 0.000 description 1
- VEGGRTFDFMUBPD-ONEGZZNKSA-N Fumarprotocetraric acid Chemical compound O1C2=C(C)C(C(O)=O)=C(O)C(COC(=O)\C=C\C(O)=O)=C2OC(=O)C2=C1C(C=O)=C(O)C=C2C VEGGRTFDFMUBPD-ONEGZZNKSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- RQGOSSYDPQTDRA-UHFFFAOYSA-N Lobaric acid Natural products O=C1OC2=CC(O)=C(C(O)=O)C(CCCCC)=C2OC2=CC(OC)=C(C(=O)CCCC)C=C21 RQGOSSYDPQTDRA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000893976 Nannizzia gypsea Species 0.000 description 1
- 101100390536 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) erg-6 gene Proteins 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 241000192656 Nostoc Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000031810 Ramalina menziesii Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000591119 Trichophyton sp. Species 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000001355 anti-mycobacterial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003926 antimycobacterial agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000003816 axenic effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- QJIHLKQEDOWOBW-UHFFFAOYSA-N fumarprotocetraric acid Natural products Cc1cc(O)c(C=O)c2Oc3c(C)c(C(=O)O)c(O)c(CC(=O)OC=CC(=O)O)c3OC(=O)c12 QJIHLKQEDOWOBW-UHFFFAOYSA-N 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 150000005165 hydroxybenzoic acids Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- AMKYESDOVDKZKV-UHFFFAOYSA-N o-Orsellinic acid Natural products CC1=CC(O)=CC(O)=C1C(O)=O AMKYESDOVDKZKV-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- WZYZDHVPSZCEEP-UHFFFAOYSA-N protolichesterinic acid Natural products CCCCCCCCCCCCCC1OC(=O)C(=C)C1C(O)=O WZYZDHVPSZCEEP-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000024053 secondary metabolic process Effects 0.000 description 1
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 1
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- ICTZCAHDGHPRQR-UHFFFAOYSA-N usnic acid Natural products OC1=C(C)C(O)=C(C(C)=O)C2=C1C1(C)C(O)=C(C(=O)C)C(=O)C=C1O2 ICTZCAHDGHPRQR-UHFFFAOYSA-N 0.000 description 1
- 229940004858 usnic acid Drugs 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/09—Lichens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0522200A GB2415379B (en) | 2003-03-31 | 2003-03-31 | Methyl-ß-orcinolcarboxylate from lichen (everniasrum cirrhatum) for use for the treatment of cancer |
PCT/IN2003/000097 WO2004087128A1 (en) | 2003-03-31 | 2003-03-31 | Methyl-β-orcinolcarboxylate from lichen (everniastrum cirrhatum) for use for the treatment of fungal infections and cancer |
AU2003226628A AU2003226628A1 (en) | 2003-03-31 | 2003-03-31 | METHYL-Beta-ORCINOLCARBOXYLATE FROM LICHEN (EVERNIASTRUM CIRRHATUM) FOR USE FOR THE TREATMENT OF FUNGAL INFECTIONS AND CANCER |
JP2004570066A JP4498930B2 (en) | 2003-03-31 | 2003-03-31 | Methyl-β-orcinol carboxylate from lichen plant (Everniastrum cirrhatum) for use in the treatment of fungal infections and cancer |
DE10394214T DE10394214T5 (en) | 2003-03-31 | 2003-03-31 | Lichen methyl B-orcinol carboxylate (Everniastrum cirrhatum) for use in the treatment of fungal infections and cancer |
CA002521055A CA2521055A1 (en) | 2003-03-31 | 2003-03-31 | Methyl-.beta.-orcinolcarboxylate from lichen (everniastrum cirrhatum) for use for the treatment of fungal infections and cancer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2003/000097 WO2004087128A1 (en) | 2003-03-31 | 2003-03-31 | Methyl-β-orcinolcarboxylate from lichen (everniastrum cirrhatum) for use for the treatment of fungal infections and cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004087128A1 true WO2004087128A1 (en) | 2004-10-14 |
Family
ID=33104946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2003/000097 WO2004087128A1 (en) | 2003-03-31 | 2003-03-31 | Methyl-β-orcinolcarboxylate from lichen (everniastrum cirrhatum) for use for the treatment of fungal infections and cancer |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP4498930B2 (en) |
AU (1) | AU2003226628A1 (en) |
CA (1) | CA2521055A1 (en) |
DE (1) | DE10394214T5 (en) |
GB (1) | GB2415379B (en) |
WO (1) | WO2004087128A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006137172A1 (en) * | 2005-06-24 | 2006-12-28 | Taiyo Kagaku Co., Ltd. | Pest control agent of fungi or parasites for fish |
CN115989072A (en) * | 2020-07-27 | 2023-04-18 | 兽医医药动力学有限责任公司 | Lichen extract-based formulation for cervidae animals |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010202562A (en) * | 2009-03-03 | 2010-09-16 | Ogawa & Co Ltd | Phenol-based antimicrobial agent |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05271064A (en) * | 1991-11-27 | 1993-10-19 | Dainippon Jochugiku Co Ltd | Antibacterial agent for methicillin-resistant staphylococcus aureus and infection preventing method using the agent |
-
2003
- 2003-03-31 AU AU2003226628A patent/AU2003226628A1/en not_active Abandoned
- 2003-03-31 DE DE10394214T patent/DE10394214T5/en not_active Withdrawn
- 2003-03-31 GB GB0522200A patent/GB2415379B/en not_active Expired - Fee Related
- 2003-03-31 WO PCT/IN2003/000097 patent/WO2004087128A1/en active Application Filing
- 2003-03-31 JP JP2004570066A patent/JP4498930B2/en not_active Expired - Fee Related
- 2003-03-31 CA CA002521055A patent/CA2521055A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05271064A (en) * | 1991-11-27 | 1993-10-19 | Dainippon Jochugiku Co Ltd | Antibacterial agent for methicillin-resistant staphylococcus aureus and infection preventing method using the agent |
Non-Patent Citations (4)
Title |
---|
CACCAMESE S ET AL: "METHYL BETA ORCINOLCARBOXYLATE AND DEPSIDES FROM PARMELIA-FURFURACEA", JOURNAL OF NATURAL PRODUCTS (LLOYDIA), vol. 48, no. 1, 1985, pages 157 - 158, XP009024129, ISSN: 0163-3864 * |
CACCAMESE S ET AL: "METHYL-BETA-ORCINOLCARBOXYLATE AND ATRANOL FROM THE LICHEN STEREOCAULON-VESUVIANUM", JOURNAL OF NATURAL PRODUCTS (LLOYDIA), vol. 49, no. 6, 1986, pages 1159 - 1160, XP009024140, ISSN: 0163-3864 * |
DATABASE WPI Section Ch Week 199346, Derwent World Patents Index; Class B05, AN 1993-365135, XP002267625 * |
SHAHI SUSHIL K ET AL: "Use of lichen as antifungal drug against superficial fungal infections", JOURNAL OF MEDICINAL AND AROMATIC PLANT SCIENCES, vol. 22-23, no. 4A-1A, 2000, pages 169 - 172, XP009024139 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006137172A1 (en) * | 2005-06-24 | 2006-12-28 | Taiyo Kagaku Co., Ltd. | Pest control agent of fungi or parasites for fish |
CN115989072A (en) * | 2020-07-27 | 2023-04-18 | 兽医医药动力学有限责任公司 | Lichen extract-based formulation for cervidae animals |
Also Published As
Publication number | Publication date |
---|---|
GB2415379B (en) | 2007-10-31 |
CA2521055A1 (en) | 2004-10-14 |
GB0522200D0 (en) | 2005-12-07 |
DE10394214T5 (en) | 2006-03-16 |
AU2003226628A1 (en) | 2004-10-25 |
JP4498930B2 (en) | 2010-07-07 |
JP2006514969A (en) | 2006-05-18 |
GB2415379A (en) | 2005-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Omar et al. | Antimicrobial activity of extracts of eastern North American hardwood trees and relation to traditional medicine | |
Huang et al. | Antibacterial activity of Artemisia asiatica essential oil against some common respiratory infection causing bacterial strains and its mechanism of action in Haemophilus influenzae | |
Vila et al. | Composition and biological activity of the essential oil from leaves of Plinia cerrocampanensis, a new source of α-bisabolol | |
Haghdoost et al. | Antifungal activity and influence of propolis against germ tube formation as a critical virulence attribute by clinical isolates of Candida albicans | |
Koroishi et al. | In vitro antifungal activity of extracts and neolignans from Piper regnellii against dermatophytes | |
Chandra et al. | Antioxidant and antimicrobial activity displayed by a fungal endophyte Alternaria alternata isolated from Picrorhiza kurroa from Garhwal Himalayas, India | |
Alves-Silva et al. | Unveiling the bioactive potential of the essential oil of a Portuguese endemism, Santolina impressa | |
Ourabah et al. | Anti-Candida albicans biofilm activity of extracts from two selected indigenous Algerian plants: Clematis flammula and Fraxinus angustifolia | |
Hoda et al. | Anti-melanogenic activity of Myristica fragrans extract against Aspergillus fumigatus using phenotypic based screening | |
US20070099993A1 (en) | Antimicrobial and anticancer properties of methyl-beta-orcinolcarboxylate from lichen (Everniastrum cirrhatum) | |
Gholampour-Azizi et al. | In vitro antifungal activity of Cucumis melo on Candida albicans | |
Kikowska et al. | antimicrobial activity of extracts and their fractions from three L. species | |
Karagoz et al. | Antiviral and cytotoxic activity of some lichen extracts | |
Zhuo et al. | The phytochemicals with antagonistic activities toward pathogens of a disease complex caused by Meloidogyne incognita and Ralstonia solanacearum | |
WO2004087128A1 (en) | Methyl-β-orcinolcarboxylate from lichen (everniastrum cirrhatum) for use for the treatment of fungal infections and cancer | |
Pandey | Lichens: a resource chest of herbal antimicrobial compounds | |
GB2432530A (en) | Methyl-beta-orcinol carboxylate for use in treating fungal infections and antifungal compositions comprising it | |
Dhankhar et al. | Safety and efficacy of green foliage in the treatment of fungal infections and associated clinical conditions | |
Khaliq et al. | Evolution of Cytotoxicity, Antioxidant, and Antimicrobial Studies of Sugarcane (Saccharum officinarum) Roots Extracts. | |
ZA200507919B (en) | Methyl-B-orcinolcarboxylate from linchen (everniastrum cirrhatum) for use for the treatment of fungal infections and cancer | |
SSGGGGGGGGSGGGGGGGGGGS | cio, Patent Application Publication (io) Pub. No.: US 2004/0198815A1 | |
Hanafiah et al. | Antibacterial and biofilm inhibition activities of Melastoma malabathricum stem bark extract against Streptococcus mutans | |
GB2438552A (en) | Ethanolic extracts of Everniastrum Cirrhatum for use in the treatment of fungal infections | |
De Nkainsa et al. | Phytochemical analysis and in vitro antimicrobial screenings of the methanolic stem bark extract and constituents of Parkia bicolor A. Chev.(Leguminosae) | |
Taufiq et al. | Effect of ethyl acetate crude extract of Lasiodiplodia pseudotheobromae IBRL OS-64 against oral cavity bacteria with emphasis on Streptococcus mutans |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 3824/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004570066 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2521055 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 0522200.5 Country of ref document: GB Ref document number: 0522200 Country of ref document: GB |
|
RET | De translation (de og part 6b) |
Ref document number: 10394214 Country of ref document: DE Date of ref document: 20060316 Kind code of ref document: P |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10394214 Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase | ||
122 | Ep: pct application non-entry in european phase | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8607 |